Back to Browse Journals » International Journal of Nanomedicine » Volume 7

Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy

Authors Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A

Published Date July 2012 Volume 2012:7 Pages 3637—3657

DOI http://dx.doi.org/10.2147/IJN.S23696

Received 9 January 2012, Accepted 28 February 2012, Published 20 July 2012

Evelina Miele,1,* Gian Paolo Spinelli,2,* Ermanno Miele,3 Enzo Di Fabrizio,3,6 Elisabetta Ferretti,4 Silverio Tomao,2 Alberto Gulino,1,5

1Department of Molecular Medicine, 2Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 3Nanostructures, Istituto Italiano di Tecnologia, via Morego, 30, 16163 Genova, 4Department of Experimental Medicine, Sapienza University of Rome, Rome, 5Center for Life Nanoscience, Istituto Italiano di Tecnologia, Rome, Italy, 6BIONEM lab, University of Magna Graecia, Campus S. Venuta, Viale Europa 88100 Catanzaro, Italy

*These authors contributed equally to this work

Abstract: During recent decades there have been remarkable advances and profound changes in cancer therapy. Many therapeutic strategies learned at the bench, including monoclonal antibodies and small molecule inhibitors, have been used at the bedside, leading to important successes. One of the most important advances in biology has been the discovery that small interfering RNA (siRNA) is able to regulate the expression of genes, by a phenomenon known as RNA interference (RNAi). RNAi is one of the most rapidly growing fields of research in biology and therapeutics. Much research effort has gone into the application of this new discovery in the treatment of various diseases, including cancer. However, even though these molecules may have potential and strong utility, some limitations make their clinical application difficult, including delivery problems, side effects due to off-target actions, disturbance of physiological functions of the cellular machinery involved in gene silencing, and induction of the innate immune response. Many researchers have attempted to overcome these limitations and to improve the safety of potential RNAi-based therapeutics. Nanoparticles, which are nanostructured entities with tunable size, shape, and surface, as well as biological behavior, provide an ideal opportunity to modify current treatment regimens in a substantial way. These nanoparticles could be designed to surmount one or more of the barriers encountered by siRNA. Nanoparticle drug formulations afford the chance to improve drug bioavailability, exploiting superior tissue permeability, payload protection, and the “stealth” features of these entities. The main aims of this review are: to explain the siRNA mechanism with regard to potential applications in siRNA-based cancer therapy; to discuss the possible usefulness of nanoparticle-based delivery of certain molecules for overcoming present therapeutic limitations; to review the ongoing relevant clinical research with its pitfalls and promises; and to evaluate critically future perspectives and challenges in siRNA-based cancer therapy.

Keywords: small interfering RNA, nanoparticles, cancer therapy, delivery strategies, biological barriers, clinical trials

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Targeting nanomaterials: future drugs for cancer chemotherapy

Zhang Y, Chen T

International Journal of Nanomedicine 2012, 7:5283-5286

Published Date: 10 October 2012

Effects of hydrothermal treatment on the properties of nanoapatite crystals

Liang W, Niu Y, Ge S, Song S, Su J, Luo Z

International Journal of Nanomedicine 2012, 7:5151-5158

Published Date: 28 September 2012

Amphiphilic graft copolymer based on poly(styrene-co-maleic anhydride) with low molecular weight polyethylenimine for efficient gene delivery

Duan XP, Xiao JS, Yin Q, Zhang ZW, Mao SR, Li YP

International Journal of Nanomedicine 2012, 7:4961-4972

Published Date: 14 September 2012

Biofunctionalization of a titanium surface with a nano-sawtooth structure regulates the behavior of rat bone marrow mesenchymal stem cells

Zhang WJ, Li ZH, Liu Y, Ye DX, Li JH, Xu LY, Wei B, Zhang XL, Liu XY, Jiang XQ

International Journal of Nanomedicine 2012, 7:4459-4472

Published Date: 13 August 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Nanofibrillar scaffolds induce preferential activation of Rho GTPases in cerebral cortical astrocytes

Tiryaki VM, Ayres VM, Khan AA, Ahmed I, Shreiber DI, Meiners S

International Journal of Nanomedicine 2012, 7:3891-3905

Published Date: 20 July 2012

Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes

Pang Z, Gao H, Chen J, Shen S, Zhang B, Ren J, Guo L, Qian Y, Jiang X, Mei H

International Journal of Nanomedicine 2012, 7:3421-3432

Published Date: 6 July 2012

Magnetic responsive hydroxyapatite composite scaffolds construction for bone defect reparation

Zeng XB, Hu H, Xie LQ, Lan F, Jiang W, Wu Y, Gu ZW

International Journal of Nanomedicine 2012, 7:3365-3378

Published Date: 4 July 2012

An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma

Shen M, Gong FM, Pang PF, Zhu KS, Meng XC, Wu C, Wang J, Shan H, Shuai XT

International Journal of Nanomedicine 2012, 7:3319-3332

Published Date: 2 July 2012